Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sibling allogenic umbilical cord blood nuclear cells
- Development stage
- Unknown
- Lead developer
- Kochi University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Sibling allogenic umbilical cord blood nuclear cells (Allo-CBRek) is an investigational cell therapy consisting of the total nucleated cell (TNC) fraction derived from the umbilical cord blood of an HLA-matched or partially matched sibling. This therapeutic approach is being evaluated for pediatric neurological conditions, specifically cerebral palsy and moderate-to-severe hypoxic-ischemic encephalopathy (HIE). The therapy is hypothesized to exert neuroprotective and regenerative effects through the paracrine secretion of neurotrophic factors and anti-inflammatory cytokines, which may modulate the immune response and promote endogenous neural repair in the damaged brain. In clinical protocols, the cells are typically administered via intravenous infusion, often accompanied by a short course of immunosuppressive agents like cyclosporine and prednisolone to mitigate the risk of graft-versus-host disease or cell rejection.
- Other names
- allogenic sibling umbilical cord blood nuclear cellssibling umbilical cord blood mononuclear cellssibling allogenic umbilical cord blood total nucleated cells
Beyond the preview
Go deeper on sibling allogenic umbilical cord blood nuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sibling allogenic umbilical cord blood nuclear cells.